Allspring Global Investments Holdings LLC Lowers Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Allspring Global Investments Holdings LLC trimmed its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 19.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 251,137 shares of the biopharmaceutical company’s stock after selling 62,482 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Vanda Pharmaceuticals were worth $1,060,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Acadian Asset Management LLC raised its stake in Vanda Pharmaceuticals by 53.7% in the third quarter. Acadian Asset Management LLC now owns 1,750,655 shares of the biopharmaceutical company’s stock valued at $7,559,000 after purchasing an additional 611,564 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Vanda Pharmaceuticals by 19.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 965,856 shares of the biopharmaceutical company’s stock valued at $4,172,000 after purchasing an additional 156,896 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in Vanda Pharmaceuticals in the third quarter valued at approximately $2,065,000. Los Angeles Capital Management LLC raised its stake in Vanda Pharmaceuticals by 42.2% in the third quarter. Los Angeles Capital Management LLC now owns 465,954 shares of the biopharmaceutical company’s stock valued at $2,013,000 after purchasing an additional 138,284 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in Vanda Pharmaceuticals by 152.9% in the third quarter. GSA Capital Partners LLP now owns 406,019 shares of the biopharmaceutical company’s stock valued at $1,754,000 after purchasing an additional 245,495 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ VNDA opened at $4.63 on Wednesday. Vanda Pharmaceuticals Inc. has a one year low of $3.30 and a one year high of $7.00. The firm’s 50 day simple moving average is $4.26 and its two-hundred day simple moving average is $4.07. The stock has a market capitalization of $266.40 million, a P/E ratio of 92.60 and a beta of 0.76.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. The business had revenue of $45.27 million for the quarter, compared to analysts’ expectations of $37.00 million. As a group, equities analysts expect that Vanda Pharmaceuticals Inc. will post -0.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on VNDA. StockNews.com downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday. TheStreet downgraded shares of Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research note on Thursday, February 8th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.